Alireza Rezaeizade, PhD


A distinguished and accomplished scientist, Dr. Alireza Rezaeizadeh has built a career as recognized and respected expert in Medical Histology and Molecular Biology, a product of both academic accomplishment and professional efforts as scientist and proven researcher in the Department of Molecular and Cellular Endocrinology at the City of Hope. Previously, he was a researcher in the Department of Endocrinology at the University of Sydney, Australia. He was renowned lecturer in both practical and theoretical Histology over the course of several years in his native Iran. Keen deductive logic and astute analytical abilities complement advanced levels of scholarship achieved through studies toward the receipt of his Doctor of Philosophy in 2014 from the Institute of Biosciences, University Putra Malaysia. Over the course of PhD study, he focused on diabetic complication, developing a depth of knowledge in animal studies, in tandem with an array of qualitative and quantitative scientific skill sets. This wide range of abilities, as demonstrated by his extensive background in methods, in tandem with bilingual fluency and advanced laboratory expertise has provided an array of tools and competencies to facilitate consistent excellence, no matter the challenge presented.
While much of his professional success is predicted on a demonstrated strength of intellect, a relentless spirit of engaged inquiry and exceptional breadth of field knowledge. His deft technical abilities including quantitative real time PCR, Western blot, zymography ELISA, electron microscopy and more, have been instrumental as well.

Such overall technical expertise complemented by the highest standards in the deft utilization of specific Histology laboratory skills including tissue processing, microtome, tissue sectioning (microtome and cryostat), Histochemistry, immunohistochemistry and dual immunofluorescence staining, as well as the quantitative analysis of images using histology software; ImageJ, and Image-Pro Premier software; are skills that have been honed over the course of nearly two decades of academic and professional experience, Dr. Rezaeizadeh unifies such extensive background through the continuous adoption of multidisciplinary approaches, thus taking steps to ensure salience and validity of findings. This intellectual and experiential background has further enabled the production and international publishing of numerous co-authored journal articles and conference presentations in noted scholarly forums in the United States, Australia, Malaysia, Thailand and Hungary.

With a reputation for professionalism that spans two continents, He has widely published and presented the results of an exemplary and dedicated research agenda. Examination of the correlation between MomordicaCharantia and its impact on induced diabetes assessed through work with neonatal rats, has led to several breakthrough findings. Other interests include the assessment of the connective tissue growth factor/CCN2 in a dietary-induced obesity mode and the effects of ascorbic and fatty acids on wound healing, areas that each and all have significant implications for biomedical advancements.

The recipient of the honor as Researcher of the year at Rafsanjan Medical University in Rafsanjan Iran, his work has also been singled out for distinction from the Deputy Manager of Research, Education, Culture and Student, Medical University of that city. At the cusp of this career it was clear to many that he was embarking on a path of professional excellence when he was cited as Honorary Expert of the University.

Dr. Rezaeizadeh has all the hallmarks of a leader in his field. Beyond his many scientific accomplishments, he is highly personable and effective in interpersonal relations, an excellent manager and team leader with an outstanding work ethic and the requisite flexibility essential for success in research Earlier education included the receipt of a Master of Science (M.S.) in Medical Histology, Isfahan University of Medical Sciences, and a Bachelor of Science (B.S.) in Medical Laboratory Sciences, School of Medicine, Iran. While Alireza Rezaeizadeh has led a distinguished career to date, his professional future promises much to come.


For Medical Professional Viewing Only


Stemell, Inc. does not claim that therapy using StemL products cures or prevents any condition, disease or injury. All statements and opinions provided are for educational and informational purposes only, and we do not diagnose or provide medical or legal advice.

Individuals interested in any cellular or cell-free regenerative medicine therapy are urged to review all pertinent information and do their own research and due diligence before choosing to participate in any therapies. Please consult with your physician for further information and be sure to discuss any potential risks.

Please understand that Stemell, Inc. is a supplier only. Stemell, Inc. is not a sponsor, and Stemell, Inc. is not claiming to cure or treat any disorder or condition.

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.

The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.

This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.

“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else. If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.

Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.